Lasa Supergenerics Limited Bombay S.E.

LASA

INE670X01014

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:52 16/07/2024 BST			5-day change	1st Jan Change
23.84 ^INR	-1.73%		-5.96%	-20.43%

05-30	Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
04-26	Lasa Supergenerics CFO Steps Down	MT

Lasa Supergenerics Limited Announces Resignation of Minesh Bhosle as Chief Financial Officer

January 31, 2018 at 12:17 pm

Lasa Supergenerics Limited announced the resignation of Mr. Minesh Bhosle as Chief Financial Officer of the company effective from January 31, 2018.

Latest news about Lasa Supergenerics Limited

Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Lasa Supergenerics CFO Steps Down	04-26	MT
Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer	04-26	CI
Lasa Supergenerics Limited Appoints Umesh Pawar as an Additional Director (Executive Director)	03-08	CI
Lasa Supergenerics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Lasa Supergenerics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-10	CI
Lasa Supergenerics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Lasa Supergenerics Limited Announces Change in Corporate Office Address	27/07/23	CI
Lasa Supergenerics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	09/06/23	CI
Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	09/06/23	CI
Lasa Supergenerics Limited Approves Appointment of Mitti Jain as Company Secretary & Compliance Officer	21/03/23	CI
Lasa Supergenerics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Lasa Supergenerics Limited Announces Resignation of Ankita Shetty as Company Secretary and Compliance Officer	09/02/23	CI

Chart Lasa Supergenerics Limited

Duration

Period

More charts

Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
ZOETIS INC.	-7.76%	83.46B
ELANCO ANIMAL HEALTH INCORPORATED	-12.42%	6.55B
BLUESTAR ADISSEO COMPANY	+35.38%	3.95B
VIRBAC	-2.78%	3.3B
VIMIAN GROUP AB	+19.76%	1.77B
VETOQUINOL SA	-1.56%	1.29B
JINYU BIO-TECHNOLOGY CO., LTD.	-37.70%	1.01B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-42.92%	949M
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-18.24%	839M